Pfizer and Bristol-Myers Squibb (BMS) are working together on grants in support of innovative cardiovascular therapies. The goal of these grants is to improve patient care and outcomes through therapy innovation.
PLEASE NOTE: Responses to the RFP listed below should be made through the Bristol-Myers Squibb Grants and Giving website:
Request for Proposals (RFP)
Eliminating Barriers to Innovate Cardiovascular Therapies
to Improve Patient Care and Outcomes
Date RFP Issued: May 1, 2017
Clinical Area: Cardiovascular
Link to full RFP: Eliminating Barriers to Innovate Cardiovascular Therapies to Improve Patient Care and Outcomes
Due Date: June 28, 2017
Geographic Scope: United States
Specific Area of Interest: Chronic disease is the leading cause of death and disability in the United States. Accessing affordable treatments is vital for all Americans. There are many factors that may limit both patient and provider ability to access the newest and most innovative therapies including restrictive formularies, step therapy, non-medical switching, cost and cumbersome administrative processes including prior authorization and tier exception processes. The strategies employed to address these barriers may include
· Gaining an understanding of barriers from each stakeholder’s point of view (HCP, Patient, administrative staff, caregivers, others)
· Developing best practices that can inform advocacy organizations and medical societies, including the role each could play in the evolving access landscape
Questions regarding this RFP should be directed to firstname.lastname@example.org.